Cancer Treatment Today

Post-transplant lymphoproliferative disease (PTLD) remains a major complication after solid organ and allogeneic stem cell transplantation. It usually is caused by growth of lymphocytes infected with Epstein-Barr virus (EBV) in patients whose immune system is suppressed after transplantation to prevent rejection. Following titers and an individualized treatment plan including decreased immunosuppression and other agents should be chosen based on

Aplastic anemia in younger patients is generally an  immune disorders, in which the immune system attack newly forming red cells and kills them. For this reason, it is often treated with immunosuppression. The risks of supressing the immune system is greater in older people, and for this reason, the suppression of the immune system is more often used in younger patients. Older individuals and those who failed immune suppressing drugs, should go

Post-transplant lymphoproliferative disease (PTLD) remains a major complication after solid organ and allogeneic stem cell transplantation. It is usually related to outgrowth of lymphocytes infected with Epstein-Barr virus (EBV). Following titers and an individualized treatment plan including decreased immunosuppression and other agents should be chosen based on the severity and extent of disease. Some classify  PTLD into three groups(1):  Early

Risedronic acid(Atelvia)  is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and a different chemical chain

Aplastic anemia in younger patients is generally immune mediated and is treated with immunosupression. When there is no sibling donor, cyclosporine(CSA) is recommended, usually in combination with other drugs but it can also be used alone(1). First-line treatment approaches include immunosuppressive treatment using the combination of antithymocyte globulin and cyclosporine A for patients without a sibling donor and HLA identical sibling transplant

Progress in the treatment of kidney cancer has been nothing short of amazing in the past few years. Many new drugs have been introduced and FDA approved for first line therapy. This significantly expanded our armamentarium against this previously difficult to treat cancer. At the same time, rapid introduction of new agents has led to the situation in which there is there little evidence on how to select which one should be used first. The only the

Progress in the treatment of kidney cancer has been nothing short of amazing in the past few years. Many new drugs have been introduced and FDA approved for first line therapy. This significantly expanded our armamentarium against this previously difficult to treat cancer. At the same time, rapid introduction of new agents has led to the situation in which there is there little evidence on how to select which one should be used first. The only the

The human alpha gene is found on the short arm of chromosome 16 and there are two hemoglobin alpha chain genes, HBA1 and HBA2. Almost all alpha thalassemias result from a loss of one or more of the alpha genes; the more genes dropped, the more severe is the disease.  Unlike Beta-thalssemia, which is found around the Mediterranean, alpha-thalassemias is more geographically widespread and can be found in the descendents of people from Africa and Asia,

  Tamoxifen is a venerable drug that revolutionized breast cancer care when it was first introduced. More recently, it has been largely supplanted by aromatase inhibitors(AI), but tamoxifen is still useful in pre-menopausal women, in whom AIs do not work. Tamoxifen has a variety of bothersome side effects, related mostly to forced early menopause. In the trials reviewed by Kennecke al, hot flushes were commonly reported (40% to 60%).In the MA

DecisionDx is a molecular diagnostic test developed at and licensed from The University of Texas M. D. Anderson Cancer Center. The test is used to prospectively predict patient outcome to treatment for various cancers. DecisionDx-UM is a more specific prognostic test that determines the metastatic risk associated with ocular melanoma tumors of the eye. The test classifies tumors as Class 1A (low metastatic risk), Class 1B (long-term metastatic risk),